<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40926068</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-6866</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Die Anaesthesiologie</Title><ISOAbbreviation>Anaesthesiologie</ISOAbbreviation></Journal><ArticleTitle>[Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors in perioperative medicine : Effects, side effects and current recommendations].</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00101-025-01580-z</ELocationID><Abstract><AbstractText>Sodium-glucose Cotransporter 2 (SGLT-2)&#xa0;inhibitors are oral antidiabetic drugs that were developed for the treatment of patients with diabetes mellitus and are now also approved for treating chronic heart failure and chronic kidney disease. By inhibiting SGLT&#x2011;2 in the proximal renal tubule, urinary excretion of glucose is increased. Large randomized trials have demonstrated improved glycemic control, reduced cardiovascular events and lower mortality but also an increased risk of urogenital infections and dehydration. Of particular concern is an increasing number of reports describing postoperative (euglycemic) ketoacidosis in patients on treatment with SGLT-2&#xa0;inhibitors, which is a&#xa0;rare but potentially life-threatening side effect which is difficult to detect. The extremely limited data situation is reflected in the heterogeneous recommendations, surgical stress, prolonged fasting and metabolic changes are considered key triggers. International guidelines recommend withholding SGLT-2&#xa0;inhibitors 3-4&#xa0;days before elective surgery, whereas an increase in undesired events has been described when discontinuing the medication in patients with heart failure. This indicates that a&#xa0;one-size-fits-all approach is unsuitable and an individualized, risk-stratified strategy that considers the risk of surgery, fasting duration and ketone monitoring appears to be more appropriate. The lack of evidence for the approach in emergency situations, limited availability of blood ketone testing and unclear guidance on when to restart treatment further complicate perioperative management. This review outlines the effects and side effects of SGLT-2&#xa0;inhibitors and summarizes the current recommendations for perioperative management.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nienhaus</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r An&#xe4;sthesiologie, Universit&#xe4;tsklinikum D&#xfc;sseldorf, Heinrich-Heine-Universit&#xe4;t, Moorenstr.&#xa0;5, 40225, D&#xfc;sseldorf, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenge</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r An&#xe4;sthesiologie, Universit&#xe4;tsklinikum D&#xfc;sseldorf, Heinrich-Heine-Universit&#xe4;t, Moorenstr.&#xa0;5, 40225, D&#xfc;sseldorf, Deutschland. theresa.tenge@med.uni-duesseldorf.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riesemann</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r An&#xe4;sthesiologie, Universit&#xe4;tsklinikum D&#xfc;sseldorf, Heinrich-Heine-Universit&#xe4;t, Moorenstr.&#xa0;5, 40225, D&#xfc;sseldorf, Deutschland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Klinik f&#xfc;r An&#xe4;sthesiologie und Operative Intensivmedizin, Universit&#xe4;tsklinikum Augsburg, Stenglinstra&#xdf;e&#xa0;2, 86156, Augsburg, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kindgen-Milles</LastName><ForeName>Detlef</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r An&#xe4;sthesiologie, Universit&#xe4;tsklinikum D&#xfc;sseldorf, Heinrich-Heine-Universit&#xe4;t, Moorenstr.&#xa0;5, 40225, D&#xfc;sseldorf, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lurati Buse</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r An&#xe4;sthesiologie, Universit&#xe4;tsklinikum D&#xfc;sseldorf, Heinrich-Heine-Universit&#xe4;t, Moorenstr.&#xa0;5, 40225, D&#xfc;sseldorf, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#x2bc;Pembele</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r An&#xe4;sthesiologie, Universit&#xe4;tsklinikum D&#xfc;sseldorf, Heinrich-Heine-Universit&#xe4;t, Moorenstr.&#xa0;5, 40225, D&#xfc;sseldorf, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r An&#xe4;sthesiologie, Universit&#xe4;tsklinikum D&#xfc;sseldorf, Heinrich-Heine-Universit&#xe4;t, Moorenstr.&#xa0;5, 40225, D&#xfc;sseldorf, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Natrium-Glukose-Co-Transporter-2 (SGLT-2)-Hemmer in der perioperativen Medizin : Wirkungen, Nebenwirkungen sowie aktuelle Empfehlungen.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Anaesthesiologie</MedlineTA><NlmUniqueID>9918384886806676</NlmUniqueID><ISSNLinking>2731-6858</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Natrium-Glukose-Co-Transporter-2 (SGLT-2)-Hemmer sind orale Antidiabetika, die inzwischen auch unabh&#xe4;ngig von einem Diabetes mellitus zur Behandlung der chronischen Herzinsuffizienz und der chronischen Niereninsuffizienz zugelassen sind. &#xdc;ber eine Inhibierung des Natrium-Glucose-Co-Transporters&#x2011;2 im proximalen Nierentubulus kommt es zur vermehrten Ausscheidung von Glucose mit dem Urin, was mit einer signifikanten Reduktion kardiovaskul&#xe4;rer Komplikationen und geringerer Sterblichkeit, aber auch urogenitalen Infektionen und volumenmangelbedingten Exsikkosen verbunden ist. Besonders relevant sind jedoch sich h&#xe4;ufende Fallberichte postoperativer (euglyk&#xe4;mischer) Ketoacidosen bei Patienten unter SGLT-2-Hemmer-Therapie, eine seltene, aber schwer erkennbare und potenziell lebensbedrohliche Nebenwirkung. Die &#xe4;u&#xdf;erst limitierte Datenlage spiegelt sich in heterogenen Empfehlungen wider. W&#xe4;hrend internationale Leitlinien ein Absetzen von SGLT-2-Hemmern 3 bis 4&#xa0;Tage vor elektiven Eingriffen empfehlen, wurde bei Patienten mit einer Herzinsuffizienz eine Zunahme unerw&#xfc;nschter Ereignisse bei Absetzen der Medikation beschrieben. Dies deutet darauf hin, dass ein &#x201e;One-size-fits-all&#x201c;-Ansatz unzureichend ist und ein individuelles risikostratifiziertes Vorgehen unter Beachtung von Operationsrisiko, N&#xfc;chternzeit und Ketonbestimmung angebracht scheint. Fehlende Evidenz f&#xfc;r das Vorgehen in Notfallsituationen, begrenzte Verf&#xfc;gbarkeit von Blut-Keton-Tests und ungenaue Angaben zur Wiederaufnahme der Therapie erschweren das Management. Diese &#xdc;bersichtsarbeit beleuchtet die Wirkungen und Nebenwirkungen von SGLT-2-Hemmern und fasst die aktuellen Empfehlungen bez&#xfc;glich des perioperativen Managements zusammen.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Ketoacidosis</Keyword><Keyword MajorTopicYN="N">Kidney disease</Keyword><Keyword MajorTopicYN="N">Preoperative medication</Keyword></KeywordList><CoiStatement>Einhaltung ethischer Richtlinien. Interessenkonflikt: R.&#xa0;M&#x2bc;Pembele und S.&#xa0;Roth erhalten von der Deutschen Gesellschaft f&#xfc;r An&#xe4;sthesiologie und Intensivmedizin (DGAI) eine F&#xf6;rderung einer deutschlandweiten Multizenterstudie zum Thema des Artikels. T.&#xa0;Tenge erhielt von der DAAD, DFG und EU Unterst&#xfc;tzung zur Teilnahme an Meetings oder Reisekostenzusch&#xfc;sse. J.&#xa0;Nienhaus, S.&#xa0;Riesemann, D.&#xa0;Kindgen-Milles, G.&#xa0;Lurati Buse geben an, dass kein Interessenkonflikt besteht. F&#xfc;r diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgef&#xfc;hrt. F&#xfc;r die aufgef&#xfc;hrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40926068</ArticleId><ArticleId IdType="doi">10.1007/s00101-025-01580-z</ArticleId><ArticleId IdType="pii">10.1007/s00101-025-01580-z</ArticleId></ArticleIdList><ReferenceList><Title>Literatur</Title><Reference><Citation>Ddg (2023) Therapie des Typ-1-Diabetes. AWMF, S&#xa0;151</Citation></Reference><Reference><Citation>Administration USFaD (2022) FDA-revises-labels-of-SGLT2-inhibitors-for-diabetes-to-include-warnings-about-too-much-acid-in-the-blood-and-serious-urinary-tract-infections. FDA</Citation></Reference><Reference><Citation>Administration USFaD (2017) FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). FDA</Citation></Reference><Reference><Citation>Agency&#xa0;EM (2016) EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. EMA</Citation></Reference><Reference><Citation>Agency&#xa0;EM (2021) Forxiga (dapagliflozin) 5&#x202f;mg should no longer be used for the treatment of Type&#xa0;1 Diabetes Mellitus. EMA, S&#xa0;3</Citation></Reference><Reference><Citation>Alkabbani&#xa0;W, Pelletier&#xa0;R, Gamble&#xa0;JM (2021) Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events. Am J Epidemiol 190:1572&#x2013;1581</Citation><ArticleIdList><ArticleId IdType="pubmed">33751032</ArticleId><ArticleId IdType="doi">10.1093/aje/kwab052</ArticleId></ArticleIdList></Reference><Reference><Citation>Anker&#xa0;SD, Butler&#xa0;J, Filippatos&#xa0;G et&#xa0;al (2021) Empagliflozin in Heart Failure with a&#xa0;Preserved Ejection Fraction. N&#xa0;Engl J Med 385:1451&#x2013;1461</Citation><ArticleIdList><ArticleId IdType="pubmed">34449189</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2107038</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc4;rzteschaft&#xa0;ADD (2023) Ketoazidose unter SGLT-2-Inhibitoren. Arzneimittelverordnung Prax 50:55&#x2013;56</Citation></Reference><Reference><Citation>Baden-W&#xfc;rttemberg&#xa0;GP (2025) SGLT-2-Hemmer (Gliflozine) &#x2013; konsentierte Hinweise zur wirtschaftlichen Verordnung bei Erwachsenen</Citation></Reference><Reference><Citation>Bonner&#xa0;C, Kerr-Conte&#xa0;J, Gmyr&#xa0;V et&#xa0;al (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21:512&#x2013;517</Citation><ArticleIdList><ArticleId IdType="pubmed">25894829</ArticleId><ArticleId IdType="doi">10.1038/nm.3828</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown&#xa0;F, Mccoll&#xa0;T (2018) Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A&#xa0;Case Report. J&#xa0;Emerg Med 54:109&#x2013;111</Citation><ArticleIdList><ArticleId IdType="pubmed">29157798</ArticleId><ArticleId IdType="doi">10.1016/j.jemermed.2017.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundes&#xe4;rztekammer&#xa0;KB, Awmf (2023) Nationale Versorgungsleitlinie Typ-2-Diabetes. AWMF, S&#xa0;156</Citation></Reference><Reference><Citation>Bundesauschuss&#xa0;G (2020) Beschluss des Gemeinsamen Bundesausschusses &#xfc;ber die Veranlassung einer erneuten Nutzenbewertung nach &#xa7;&#xa0;35a Abs.&#xa0;1 SGB&#xa0;V i.&#x202f;V.&#x202f;m. &#xa7;&#xa0;3 Abs.&#xa0;1 Nr.&#xa0;4 AM-NutzenV und 5. In: Kapitel &#xa7;&#xa0;13 VerfO: Anlage&#xa0;XII &#x2013; Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach &#xa7;&#xa0;35a&#xa0;SGB&#xa0;V</Citation></Reference><Reference><Citation>Chow E, Clement S, Garg R (2023) Euglycemic diabetic ketoacidosis in the era of SGLT-2&#xa0;inhibitors. BMJ Open Diabetes Res Care 11:</Citation></Reference><Reference><Citation>Grandt&#xa0;DVL, Schubert&#xa0;I (2023) Arzneimittelreport. In: Schriftreihe zur Gesundheitsanalyse. BARMER Krankenkasse,</Citation></Reference><Reference><Citation>Dhatariya&#xa0;KK (2022) The management of diabetic ketoacidosis in adults&#x2014;An updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet Med 39:e14788</Citation><ArticleIdList><ArticleId IdType="pubmed">35224769</ArticleId><ArticleId IdType="doi">10.1111/dme.14788</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit AA, Bateman BT, Hawn MT et&#xa0;al (2025) Preoperative SGLT2 Inhibitor Use and Postoperative Diabetic Ketoacidosis. JAMA Surg</Citation></Reference><Reference><Citation>El-Boghdadly&#xa0;K, Dhesi&#xa0;J, Fabb&#xa0;P et&#xa0;al (2025) Elective peri-operative management of adults taking glucagon-like peptide&#x2011;1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2&#xa0;inhibitors: a&#xa0;multidisciplinary consensus statement: A&#xa0;consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association. Anaesthesia 80:412&#x2013;424</Citation><ArticleIdList><ArticleId IdType="pubmed">39781571</ArticleId><ArticleId IdType="pmc">11885194</ArticleId><ArticleId IdType="doi">10.1111/anae.16541</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca-Correa&#xa0;JI, Correa-Rotter&#xa0;R (2021) Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A&#xa0;Review. Front Med 8:777861</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.777861</ArticleId></ArticleIdList></Reference><Reference><Citation>Halvorsen&#xa0;S, Mehilli&#xa0;J, Cassese&#xa0;S et&#xa0;al (2022) 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart&#xa0;J 43:3826&#x2013;3924</Citation><ArticleIdList><ArticleId IdType="pubmed">36017553</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehac270</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink&#xa0;HJL, Stefansson&#xa0;BV, Correa-Rotter&#xa0;R et&#xa0;al (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N&#xa0;Engl J Med 383:1436&#x2013;1446</Citation><ArticleIdList><ArticleId IdType="pubmed">32970396</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2024816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ireland&#xa0;JT, Thomson&#xa0;WS (1973) Euglycemic diabetic ketoacidosis. Br Med&#xa0;J 3:107</Citation><ArticleIdList><ArticleId IdType="pubmed">4197963</ArticleId><ArticleId IdType="pmc">1586549</ArticleId><ArticleId IdType="doi">10.1136/bmj.3.5871.107-a</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrends&#xa0;JJB, Deutzmann&#xa0;R, Ehmke&#xa0;H, Frings&#xa0;S (2021) Duale Reihe Physiologie. Thieme</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/b000000462</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja&#xa0;D, Nasa&#xa0;P, Jain&#xa0;R et&#xa0;al (2023) Sodium-glucose Cotransporter&#x2011;2 Inhibitors induced euglycemic diabetic ketoacidosis: A&#xa0;meta summary of case reports. World J Diabetes 14:1314&#x2013;1322</Citation><ArticleIdList><ArticleId IdType="pubmed">37664476</ArticleId><ArticleId IdType="pmc">10473945</ArticleId><ArticleId IdType="doi">10.4239/wjd.v14.i8.1314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kietaibl&#xa0;AT, Fasching&#xa0;P, Glaser&#xa0;K et&#xa0;al (2022) New Diabetic Medication Sodium-Glucose Cotransporter&#x2011;2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A&#xa0;Case Report and Review of Literature. Front Surg 9:828649</Citation><ArticleIdList><ArticleId IdType="pubmed">35402477</ArticleId><ArticleId IdType="pmc">8987984</ArticleId><ArticleId IdType="doi">10.3389/fsurg.2022.828649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kietaibl&#xa0;AT, Huber&#xa0;J, Clodi&#xa0;M et&#xa0;al (2023) Position statement: surgery and diabetes mellitus (Update 2023). Wien Klin Wochenschr 135:256&#x2013;271</Citation><ArticleIdList><ArticleId IdType="pubmed">37101047</ArticleId><ArticleId IdType="pmc">10133078</ArticleId><ArticleId IdType="doi">10.1007/s00508-022-02121-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamperti&#xa0;M, Romero&#xa0;CS, Guarracino&#xa0;F et&#xa0;al (2025) Preoperative assessment of adults undergoing elective noncardiac surgery: Updated guidelines from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol 42:1&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">39492705</ArticleId><ArticleId IdType="doi">10.1097/EJA.0000000000002069</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine&#xa0;MJ (2017) Empagliflozin for Type&#xa0;2 Diabetes Mellitus: An Overview of Phase&#xa0;3 Clinical Trials. Curr Diabetes Rev 13:405&#x2013;423</Citation><ArticleIdList><ArticleId IdType="pubmed">27296042</ArticleId><ArticleId IdType="pmc">5543566</ArticleId><ArticleId IdType="doi">10.2174/1573399812666160613113556</ArticleId></ArticleIdList></Reference><Reference><Citation>Li&#xa0;CX, Liu&#xa0;TT, Zhang&#xa0;Q et&#xa0;al (2023) Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type&#xa0;2 diabetes: a&#xa0;meta-analysis of cohort studies. Front Pharmacol 14:1275060</Citation><ArticleIdList><ArticleId IdType="pubmed">37905204</ArticleId><ArticleId IdType="pmc">10613530</ArticleId><ArticleId IdType="doi">10.3389/fphar.2023.1275060</ArticleId></ArticleIdList></Reference><Reference><Citation>Li&#xa0;D, Wang&#xa0;T, Shen&#xa0;S et&#xa0;al (2017) Urinary tract and genital infections in patients with type&#xa0;2 diabetes treated with sodium-glucose co-transporter 2&#xa0;inhibitors: A&#xa0;meta-analysis of randomized controlled trials. Diabetes Obes Metab 19:348&#x2013;355</Citation><ArticleIdList><ArticleId IdType="pubmed">27862830</ArticleId><ArticleId IdType="doi">10.1111/dom.12825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini&#xa0;GBJ, O&#x2019;meara&#xa0;E, Zieroth&#xa0;S et&#xa0;al (2022) 2022 Canadian Cardiovascular Society Guideline for Use of GLP&#x2011;1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Can J Cardiol 38:1153&#x2013;1167</Citation><ArticleIdList><ArticleId IdType="pubmed">35961754</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcmurray&#xa0;JJV, Solomon&#xa0;SD, Inzucchi&#xa0;SE et&#xa0;al (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N&#xa0;Engl J Med 381:1995&#x2013;2008</Citation><ArticleIdList><ArticleId IdType="pubmed">31535829</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1911303</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta&#xa0;AE, Zimmerman&#xa0;R (2025) Classic diabetic ketoacidosis and the euglycemic variant: Something old, something new. Cleve Clin J Med 92:33&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">39746727</ArticleId><ArticleId IdType="doi">10.3949/ccjm.92a.24075</ArticleId></ArticleIdList></Reference><Reference><Citation>Milder&#xa0;DA, Milder&#xa0;TY, Kam&#xa0;PCA (2018) Sodium-glucose co-transporter type-2&#xa0;inhibitors: pharmacology and peri-operative considerations. Anaesthesia 73:1008&#x2013;1018</Citation><ArticleIdList><ArticleId IdType="pubmed">29529345</ArticleId><ArticleId IdType="doi">10.1111/anae.14251</ArticleId></ArticleIdList></Reference><Reference><Citation>Min&#xa0;SH, Oh&#xa0;TJ, Baek&#xa0;SI et&#xa0;al (2018) Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type&#xa0;2 diabetes. Diabetes Metab 44:73&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">29074329</ArticleId><ArticleId IdType="doi">10.1016/j.diabet.2017.09.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Modzelewski&#xa0;KL, Pipilas&#xa0;A, Bosch&#xa0;NA (2024) Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure. JAMA Netw Open 7:e249305</Citation><ArticleIdList><ArticleId IdType="pubmed">38696170</ArticleId><ArticleId IdType="pmc">11066699</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.9305</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasa&#xa0;P, Chaudhary&#xa0;S, Shrivastava&#xa0;PK et&#xa0;al (2021) Euglycemic diabetic ketoacidosis: A&#xa0;missed diagnosis. World J Diabetes 12:514&#x2013;523</Citation><ArticleIdList><ArticleId IdType="pubmed">33995841</ArticleId><ArticleId IdType="pmc">8107974</ArticleId><ArticleId IdType="doi">10.4239/wjd.v12.i5.514</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal&#xa0;B, Perkovic&#xa0;V, Mahaffey&#xa0;KW et&#xa0;al (2017) Canagliflozin and Cardiovascular and Renal Events in Type&#xa0;2 Diabetes. N&#xa0;Engl J Med 377:644&#x2013;657</Citation><ArticleIdList><ArticleId IdType="pubmed">28605608</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1611925</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer&#xa0;M, Anker&#xa0;SD, Butler&#xa0;J et&#xa0;al (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N&#xa0;Engl J Med 383:1413&#x2013;1424</Citation><ArticleIdList><ArticleId IdType="pubmed">32865377</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2022190</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer&#xa0;M, Butler&#xa0;J, Zeller&#xa0;C et&#xa0;al (2023) Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure. Circulation 148:1011&#x2013;1022</Citation><ArticleIdList><ArticleId IdType="pubmed">37621153</ArticleId><ArticleId IdType="pmc">10516173</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.065748</ArticleId></ArticleIdList></Reference><Reference><Citation>Padda IS, Mahtani AU, Parmar M (2025) Sodium-Glucose Transport Protein&#xa0;2 (SGLT2) Inhibitors. In: StatPearls, Treasure Island</Citation></Reference><Reference><Citation>Raiten&#xa0;JM, Morlok&#xa0;A, D&#x2019;ambrosia&#xa0;S et&#xa0;al (2024) Perioperative Management of Patients Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Development of a&#xa0;Clinical Guideline at a&#xa0;Large Academic Medical Center. J&#xa0;Cardiothorac Vasc Anesth 38:57&#x2013;66</Citation><ArticleIdList><ArticleId IdType="pubmed">37932195</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2023.10.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock&#xa0;J, Marquard&#xa0;J, Laffel&#xa0;LM et&#xa0;al (2018) Empagliflozin as Adjunctive to Insulin Therapy in Type&#xa0;1 Diabetes: The EASE Trials. Diabetes Care 41:2560&#x2013;2569</Citation><ArticleIdList><ArticleId IdType="pubmed">30287422</ArticleId><ArticleId IdType="doi">10.2337/dc18-1749</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht&#xa0;B, Dumps&#xa0;C (2025) Effects of &#x201c;new&#x201d; antidiabetic drugs on management of anesthesia. Anaesthesiologie 74:341&#x2013;349</Citation><ArticleIdList><ArticleId IdType="pubmed">40164842</ArticleId><ArticleId IdType="doi">10.1007/s00101-025-01521-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewster&#xa0;SM (2017) Mrcp, Louise Curtis Bm, Mrcp, Ruth Poole Md, Frcp. Urin Versus Blood Ketones Pract Diabetes 34:13&#x2013;15</Citation></Reference><Reference><Citation>Shi&#xa0;Q, Nong&#xa0;K, Vandvik&#xa0;PO et&#xa0;al (2023) Benefits and harms of drug treatment for type&#xa0;2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 381:e74068</Citation><ArticleIdList><ArticleId IdType="pubmed">37024129</ArticleId><ArticleId IdType="pmc">10077111</ArticleId><ArticleId IdType="doi">10.1136/bmj-2022-074068</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon&#xa0;SD, Mcmurray&#xa0;JJV, Claggett&#xa0;B et&#xa0;al (2022) Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N&#xa0;Engl J Med 387:1089&#x2013;1098</Citation><ArticleIdList><ArticleId IdType="pubmed">36027570</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2206286</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart&#xa0;PA, Nestor&#xa0;CC, Clancy&#xa0;C et&#xa0;al (2025) The peri-operative implications of sodium-glucose co-transporter 2&#xa0;inhibitors: a&#xa0;narrative review. Anaesthesia 80:85&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pubmed">39506202</ArticleId><ArticleId IdType="doi">10.1111/anae.16461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenge T, Roth S, Ahrens E et&#xa0;al (2025) Preoperative SGLT&#x2011;2 inhibitor use and risk of adverse postoperative events: a&#xa0;single-centre retrospective observational study. Br J Anaesth</Citation></Reference><Reference><Citation>Thiruvenkatarajan&#xa0;V, Meyer&#xa0;EJ, Nanjappa&#xa0;N et&#xa0;al (2019) Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2&#xa0;inhibitors: a&#xa0;systematic review. Br J Anaesth 123:27&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pubmed">31060732</ArticleId><ArticleId IdType="doi">10.1016/j.bja.2019.03.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson&#xa0;A, Fleischmann&#xa0;KE, Smilowitz&#xa0;NR et&#xa0;al (2024) 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A&#xa0;Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 150:e351&#x2013;e442</Citation><ArticleIdList><ArticleId IdType="pubmed">39316661</ArticleId><ArticleId IdType="doi">10.1161/CIR.0000000000001285</ArticleId></ArticleIdList></Reference><Reference><Citation>Umapathysivam&#xa0;MM, Gunton&#xa0;J, Stranks&#xa0;SN et&#xa0;al (2024) Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium-Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. Diabetes Care 47:140&#x2013;143</Citation><ArticleIdList><ArticleId IdType="pubmed">37988720</ArticleId><ArticleId IdType="doi">10.2337/dc23-1163</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan&#xa0;M, Docherty&#xa0;KF, Claggett&#xa0;BL et&#xa0;al (2022) SGLT-2&#xa0;inhibitors in patients with heart failure: a&#xa0;comprehensive meta-analysis of five randomised controlled trials. Lancet 400:757&#x2013;767</Citation><ArticleIdList><ArticleId IdType="pubmed">36041474</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)01429-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao&#xa0;Z, Jin&#xa0;P, Zhang&#xa0;Y et&#xa0;al (2022) SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A&#xa0;Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med 9:826684</Citation><ArticleIdList><ArticleId IdType="pubmed">35557542</ArticleId><ArticleId IdType="pmc">9087280</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.826684</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner&#xa0;C, Deutsche Gesellschaft Fur Anasthesiologie Und&#xa0;I, Deutsche Gesellschaft Fur&#xa0;C et&#xa0;al (2024) Preoperative evaluation of adult patients before elective, non-cardiothoracic surgery : A&#xa0;joint recommendation of the German Society for Anesthesiology and Intensive Care Medicine, the German Society for Surgery and the German Society for Internal Medicine. Anaesthesiologie 73:294&#x2013;323</Citation><ArticleIdList><ArticleId IdType="pubmed">38700730</ArticleId><ArticleId IdType="pmc">11076399</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>